Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT07104812
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Autonomous Cortisol Secretion (ACS)
  • Mild Autonomous Cortisol Secretion

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Osilodrostat 1 MG — DRUG
    Osilodrostat 1 mg administered between noon and 6 pm daily, for 4 weeks

Study Details

The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and circadian cortisol/cortisone concentrations

Key Dates

Start date
Jan 14, 2026
Status verified
Feb 2026
Primary completion
Jan 31, 2027
Completion
Jan 31, 2027

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Mild autonomous cortisol secretion (MACS)
    Women and men diagnosed with MACS who are patients at Mayo Clinic.

Primary Outcome Measure

Adverse Events [ Time Frame: 4 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo ClinicRochesterMinnesota55905
Vanessa Fell, MA
[email protected]
507-266-6068

Find similar trials in Rochester, MN

By research site
Mayo Clinic· Rochester, MN

Related Studies